Nonanaplastic follicular cell-derived thyroid carcinoma:mitosis and necrosis in long-term follow-up by Skansing, Daniel Bräuner et al.
Syddansk Universitet
Nonanaplastic follicular cell-derived thyroid carcinoma
Skansing, Daniel Bräuner; Londero, Stefano Christian; Asschenfeldt, Pia; Larsen, Stine
Rosenkilde; Godballe, Christian
Published in:
European Archives of Oto-Rhino-Laryngology
DOI:
10.1007/s00405-017-4527-6
Publication date:
2017
Document version
Final published version
Document license
CC BY
Citation for pulished version (APA):
Skansing, D. B., Londero, S. C., Asschenfeldt, P., Larsen, S. R., & Godballe, C. (2017). Nonanaplastic follicular
cell-derived thyroid carcinoma: mitosis and necrosis in long-term follow-up. European Archives of Oto-Rhino-
Laryngology. DOI: 10.1007/s00405-017-4527-6
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 19. Apr. 2017
Vol.:(0123456789) 
Eur Arch Otorhinolaryngol 
DOI 10.1007/s00405-017-4527-6
HEAD AND NECK
Nonanaplastic follicular cell-derived thyroid carcinoma: mitosis 
and necrosis in long-term follow-up
Daniel Bräuner Skansing1  · Stefano Christian Londero1 · Pia Asschenfeldt2 · 
Stine Rosenkilde Larsen3 · Christian Godballe1 
Received: 8 December 2016 / Accepted: 3 March 2017 
© The Author(s) 2017. This article is published with open access at Springerlink.com
respectively. In DSS it was 95, 92 and 90%. For PDTC the 
5-, 10- and 20-year OS was 57, 40 and 25%, respectively. In 
DSS it was 71, 55 and 48%. Tumor necrosis and mitosis are 
highly significant prognostic indicators in analysis of long 
time survival of nonanaplastic follicular cell-derived thy-
roid carcinoma indicating that a simplification of the actu-
ally used criteria for poorly differentiated carcinomas may 
be justified.
Keywords Thyroid carcinoma · Long-term survival · 
Prognostic factors · Tumor necrosis · Mitosis
Introduction
Thyroid carcinoma is a relatively uncommon cancer 
accounting for approximately 1% of malignant disease; 
still it is the most frequent endocrine malignancy [1, 2]. 
Over the last decades a rise in incidence has been detected 
in several countries including Denmark and it seems that 
especially the incidentally found papillary micro-carcino-
mas are responsible for the increase [3, 4].
Nonanaplastic follicular cell-derived thyroid carcinoma 
(NAFCTC) includes differentiated- (DTC) and poorly dif-
ferentiated thyroid carcinoma (PDTC). DTC has an excel-
lent prognosis with a 10-year survival above 90% [5], while 
PDTC is situated between DTC and anaplastic carcinomas. 
In 2004, WHO recognized PDTC as a separate histologi-
cal entity and defined it as “a follicular-cell neoplasm that 
shows limited evidence of structural follicular cell differen-
tiation and occupy both morphologically and behaviorally 
an intermediate position between differentiated (follicular 
and papillary carcinomas) and undifferentiated (anaplas-
tic) carcinoma” [6]. In 2006, Hiltzik et al. found that PDTC 
defined on the basis of only mitosis and necrosis constitutes 
Abstract Nonanaplastic follicular cell-derived thyroid 
carcinoma (NAFCTC) includes differentiated- (DTC) and 
poorly differentiated thyroid carcinoma (PDTC). DTC has 
an excellent prognosis, while PDTC is situated between 
DTC and anaplastic carcinomas. Short-term studies sug-
gest that PDTC patients diagnosed only on tumor necro-
sis and/or mitosis have a prognosis similar to those diag-
nosed according to the TURIN proposal. The purpose of 
this study was to evaluate prognosis for NAFCTC based on 
long-term follow-up illuminating the significance of tumor 
necrosis and mitosis. A cohort of 225 patients with NAF-
CTC was followed more than 20 years. Age, sex, distant 
metastasis, histology, tumor size, extrathyroidal invasion, 
lymph node metastasis, tumor necrosis and mitosis were 
examined as possible prognostic factors. Median follow-up 
time for patients alive was 28 years (range 20–43 years). 
Age, distant metastasis, extrathyroidal invasion, tumor size, 
tumor necrosis and mitosis were independent prognostic 
factors in multivariate analysis for overall survival (OS). 
In disease specific survival (DSS) age was not significant. 
Using only necrosis and/or mitosis as criteria for PDTC 
the 5-, 10- and 20-year OS for DTC was 87, 79 and 69%, 
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a group of tumors that is more aggressive and homogene-
ous than PDTC defined by the WHO criteria [7]. In 2007, 
the TURIN proposal was published including necrosis 
and mitosis, as proposed by Hiltzik et  al. but also, it was 
extended with variables concerning growth pattern (solid, 
trabecular or insular) and nuclear morphology [8] mak-
ing interpretation more complicated. Controversy still 
exists regarding the diagnostic criteria [7, 9, 10]. In 2014, 
Gnemmi et al. published a comparison of the TURIN pro-
posal with Hiltzik’s histological grade not including growth 
pattern. They found similar performances in predicting 
prognosis [11], indicating that the less complicated model 
from Hiltzik et al. could be a sufficient tool for identifica-
tion of PDTC. However, the median follow-up time for 
the Hiltzik and the Gnemmi studies were only 3.5 and 5.7 
years, respectively.
The purpose of this study was to evaluate prognosis for 
NAFCTC based on long-term follow-up with focus on the 
significance of tumor necrosis and mitosis.
Materials and methods
From 1970 to 1992, 297 patients with histologically veri-
fied primary thyroid carcinoma were treated and/or fol-
lowed at Odense University Hospital, Denmark—a tertiary 
head and neck cancer center. Due to the unique Danish 
personal identity number it was possible to establish a ret-
rospective cohort study of NAFCTC patients with a long-
term follow-up. All patients came from a well-defined 
geographic area, the Region of Southern Denmark. At the 
end of the inclusion period the same pathologist (PA) did a 
complete histological revision. Autopsy findings were not 
included.
Two hundred thirty-one patients had histologically veri-
fied NAFCTC. In six cases treatment with curative intent 
was not possible and they were excluded from further anal-
ysis. Two hundred twenty-five patients were eligible for 
analysis. Three patients were lost to follow-up because of 
emigration. They were censored according to last available 
information.
Follow-up procedure for thyroid cancer was performed 
with a 3-month interval 2  years after treatment and a 
6-month interval the following 3 years. In the case of recur-
rence follow-up procedure would start over. Standard ENT 
examination was performed. Ultrasound was not yet stand-
ard procedure and was not done routinely.
Initial data concerning diagnostic procedures, treat-
ment, and histology has been shown in an earlier publica-
tion [12], while new data concerning recurrence, last con-
tact to hospital and cause of death were retrieved as part 
of the present study. The information was obtained from 
review of patient charts, contact to general practitioners 
and death certificates. In survival analysis primary end-
points were death and recurrence. Survival analysis was 
investigated as overall survival (OS) and disease specific 
survival (DSS). In OS death from all causes was consid-
ered an event. In DSS death from disease or death with 
disease were considered events. Recurrence was defined 
as persistent disease or occurrence of disease after the 
end of primary treatment confirmed by histology, cytol-
ogy and/or imaging. Patients with a residual tumor after 
primary treatment were registered with the date of recur-
rence set to be the date of diagnosis. In a few cases only 
the month of recurrence was available, thus the date of 
recurrence was listed as the first of that month. Closing 
date for the follow-up was March 1, 2013.
TNM staging was performed according to the fourth 
edition of UICC TNM classification [13]. An update to 
the seventh edition [14] was not possible due to insuffi-
cient information concerning lymph node metastasis and 
extrathyroidal invasion. Indications for radioactive iodine 
treatment (RAI) were presence of distant metastasis, 
lymph node metastasis, extrathyroidal extension and/or 
non-radical surgery.
Age at the time of diagnosis, sex, distant metasta-
sis, histological type (papillary versus follicular), tumor 
size, extrathyroidal invasion (pT4), regional lymph node 
metastasis, tumor necrosis and mitosis and were evalu-
ated as possible prognostic factors. All variables were 
dichotomized. Age had 45 years as cut-point. For tumor 
size the median was used as cut-point. Distant metasta-
sis, extrathyroidal invasion, tumor necrosis and regional 
lymph node metastasis were registered as “present” or 
“not present”. The presence of mitosis was registered as 
positive if more than one mitosis per high power field 
was observed.
Survival curves were generated using the 
Kaplan–Meier method. In univariate analysis the Mantel-
Haenzel log-rank test was used to evaluate differences 
between groups. P values < 0.05 were considered sig-
nificant. Variables identified as significant for survival 
in univariate analysis were included in a multivariate 
Weibull regression model, model fit was checked using 
Cox-Schnell residuals. Backward selection procedures 
were performed.
Medlog® (Information Analysis Corporation, Crystal 
Bay, Nevada 89402 USA) for  Windows® version 2012-8 
was used for clinical data management and data registra-
tion, and  SPSS® for MAC version 21 (IBM Corporation, 
Armonk, New York 10504-1722 USA) and STATA/IC 11 
(StataCorp LP, College Station, Texas 77845 USA) were 
used for statistical analysis.
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Results
Follow-up
Two hundred twenty-five patients were included in the 
analysis and the female:male ratio was 2.8:1. The median 
age at the time of diagnosis was 51 years (range 8–91 
years).
The median follow-up time for patients alive was 28 
years (range 20–43 years), when the three patients lost 
to follow-up were not included. They were censored 
after 3, 4 and 19 years, respectively. One hundred seven-
teen patients died during the period of follow-up (0.2–34 
years after diagnosis). The median age at the time of death 
was 75 years (range 31–99 years). During follow-up, 117 
patients died (thyroid carcinoma 45%; other disease than 
cancer 37%; other cancer 13%; accidents 2%; complica-
tions to treatment 1%; unknown 3%). Sixty-seven patients 
had recurrence. Stage and treatment of the study group are 
shown in Table 1.
Prognostic factors
Univariate analysis of patient and tumor related prognos-
tic factors are shown in Table 2. In six patients no primary 
tumor was found leaving 219 patients for analysis of histo-
logical features.
A total of 218 patients had sufficient tissue for examina-
tion of all parameters and were included in a multivariate 
analysis using death as primary endpoint. The results are 
shown in Table 3.
Surgical treatment was dichotomized with total and 
subtotal thyroidectomies in one group and less extensive 
procedures in another group. In univariate analysis surgi-
cal treatment was not significant. Patients who received 
RAI had a significantly worse prognosis compared to non-
receivers, but this difference disappeared when adjustment 
for stage was performed.
Survival
Figures  1 and 2 show Kaplan–Meier survival curves for 
NAFCTC. In OS the 5-, 10- and 20-year survival was 75, 
65 and 54%, respectively. In DSS 53 the 5-, 10- and 20-year 
survival was 84, 78 and 75%, respectively.
Figure 3 shows Kaplan–Meier survival curves for DTC 
and Hiltzik criteria group for OS. In the DTC group the 5-, 
10- and 20-year survival was 87, 79 and 69%, respectively. 
In the Hiltzik criteria group the 5-, 10- and 20-year survival 
was 57, 40 and 25%, respectively. Log rank test showed 
significantly difference between the groups (P < 0.0001).
Figure 4 shows Kaplan–Meier survival curves for DTC 
and Hiltzik criteria group for DSS. In the DTC group the 
5-, 10- and 20-year survival was 95, 92 and 90%, respec-
tively. In the Hiltzik criteria group the 5-, 10- and 20-year 
survival was 71, 55 and 48%, respectively. Log rank 
test showed significantly difference between the groups 
(P < 0.0001).
Discussion
This study is the first to evaluate the prognostic signifi-
cance of the Hiltzik criteria (tumor necrosis and mitosis) 
on NAFCTC long time survival. In general DTC displays 
an excellent prognosis and since recurrence and death from 
disease can occur after decades, a long follow-up time is 
important. In the present study, all patients were followed 
for at least 20 years. This provides an accurate 20-year sur-
vival analysis with no censoring due to a short follow-up 
time, which strengthens the study. Limitations are the treat-
ment at a single institution, a relatively small number of 
Table 1  TNM stage and treatment for 225 patients with nonanaplas-
tic follicular cell-derived thyroid carcinoma
RAI radioactive iodine treatment
#According to International Union Against Cancer (UICC) 1987, 4. 
edition
Characteristics Patients no. Percent
TNM stage#
 Stage I 99 44
 Stage II 52 23.1
 Stage III 44 19.6
 Stage IV 30 13.3
Treatment
 Surgical
  T-position
   Open biopsy 2 0.9
   Tumorectomy 5 2.2
   Hemithyroidectomy 54 24
   Subtotal thyroidectomy 51 22.7
   Total thyroidectomy 113 50.2
  N-position
   Lymph node extirpation 49 21.8
   Modified neck dissection 48 21.3
   Radical neck dissection 25 11.1
 Adjuvant
  RAI 96 42.7
  External radiotherapy 16 7.1
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patients and variation in treatment strategy since at the time 
no national or regional treatment guidelines were available 
for standardization.
An initial analysis of the study group was performed in 
1998 [12]. It was based on a relatively short follow-up time 
with a median of 10.2 years. Age above 45 years, distant 
metastasis, tumor necrosis, extrathyroidal invasion and 
p53-expression were found to be significant prognostic 
indicators. At that time PDTC was not yet recognized as a 
separate histological entity, and consequently some of the 
specimens would be re-classified as PDTC today explain-
ing the relatively poor survival results initially presented.
The aim of the present study was to evaluate long-
term prognostic factors with focus on tumor necrosis and 
Table 2  Univariate survival analysis of overall survival and disease specific survival in 225 patients with nonanaplastic follicular cell-derived 
thyroid carcinoma
Variables Patients no. 10-year OS 20-year OS P value 10-year DSS 20-year DSS P value
Age
 0–45  95 0.936 (0.9;1.0) 0.912 (0.9;1,0) 0.968 (0.9;1.0) 0.968 (0.9;1.0)
 >45  130 0.431 (0.3;0.5) 0.274 (0.2;0.4) <0.0001 0.622 (0.5;0.7) 0.560 (0.5;0.7) <0.0001
Sex
 Female  165 0.641 (0.6;0.7) 0.557 (0.5;0.6) 0.791 (0.7;0.9) 0.774 (0.7;0.8)
 Male  60 0.645 (0.5;0.8) 0.451 (0.3;0.6) 0.4456 0.765 (0.7;0.9) 0.679 (0.6;0.8) 0.2351
Tumor size
 ≤35  118 0.821 (0.8;0.9) 0.747 (0.7;0.8) 0.947 (0.9;1.0) 0.947 (0.9;1.0)
 >35  105 0.436 (0.3;0.5) 0.293 (0.2;0.4) <0.0001 0.572 (0.5;0.7) 0.501 (0.4;0.6) <0.0001
Lymph node metastasis
 Present  96 0.619 (0.5;0.7) 0.487 (0.4;0.6) 0.722 (0.6;0.8) 0.709 (0.6;0.8)
 Not present  129 0.659 (0.6;0.7) 0.561 (0.5;0.6) 0.5831 0.822 (0.8;0.9) 0.780 (0.7;0.9) 0.1847
Distant metastasis
 Present  36 0.167 (0.1;0.3) 0.111 (0.0;0.2) 0.232 (0.1;0.4) 0.193 (0.1;0.3)
 Not present  189 0.733 (0.7;0.8) 0.618 (0.6;0.7) <0.0001 0.879 (0.8;0.9) 0.850 (0.8;0.9) <0.0001
Histology
 Papillary  170 0.722 (0.7;0.8) 0,619 (0.5;0.7) 0.855 (0.8;0.9) 0.833 (0.8;0.9)
 Follicular  55 0.400 (0.3;0.5) 0.272 (0.2;0.4) <0.0001 0.535 (0.4;0.7) 0.480 (0.3;0.6) < 0.0001
Extrathyroidal invasion
 Present  73 0.420 (0.3;0.5) 0.317 (0.2;0.4) 0.550 (0.4;0.7) 0.472 (0.3;0.6)
 Not present  145 0.758 (0.7;0.8) 0.646 (0.6;0.7) <0.0001 0.889 (0.8;0.9) 0.869 (0.8;0.9) <0.0001
Necrosis
 Present  48 0.208 (0.1;0.3) 0.143 (0.0;0.2) 0.350 (0.2;0.5) 0.280 (0.1;0.4)
 Not present  171 0.770 (0.7;0.8) 0.649 (0.6;0.7) <0.0001 0.899 (0.9;1.0) 0.870 (0.8;0.9) <0.0001
Mitosis
 Present  37 0.324 (0.2;0.5) 0.162 (0.0;0.3) 0.418 (0.3;0.6) 0.383 (0.2;0.6)
 Not present  182 0.712 (0.7;0.8) 0.617 (0.6;0.7) <0.0001 0.857 (0.8;0.9) 0.821 (0.8;0.9) <0.0001
Table 3  Cox regression 
analysis of overall survival and 
disease specific survival in 218 
patients with nonanaplastic 
follicular cell-derived thyroid 
carcinoma
HR hazard ratio, CI confidence interval
Variables OS (111 events) DSS (52 events)
HR 95% CI P value HR 95% CI P value
Age >45 years 1.8 1.2–2.7 0.004 1.7 0.9–3.0 0.099
Distant metastasis 2.3 1.4–3.6 0.001 3.4 1.8–6.3 < 0.0001
Extrathyroidal invasion 1.7 1.1–2.6 0.010 2.8 1.5–5.2 0.002
Histology 1.3 0.8–2.1 0.232 1.6 0.8–3.0 0.185
Mitosis 2.0 1.3–3.2 0.004 2.0 1.1–3.9 0.032
Necrosis 2.8 1.8–4.4 <0.0001 3.8 2.1–7.0 < 0.0001
Tumor size >35 mm 1.9 1.2–3.0 0.004 3.5 1.4–8.3 0.006
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mitosis. This would allow differentiation in survival analy-
sis between DTC and PDTC according to the Hiltzik cri-
teria [7], which Gnemmi el al. [11] found to be similar to 
TURIN criteria in predicting prognosis. Our study based on 
very long observation time confirms the results by Gnemmi 
et al.
Age is generally known to be one of the most influential 
prognostic factors in DTC, but there is still disagreement 
on where to set the cut-point. In numerous studies different 
cut-points are suggested such as 40, 45, 50 and 60 years [5, 
15–20]. In our study 45 years was the cut-point, which is 
in accordance to the UICC/TNM staging system for DTC 
[14]. In the multivariate analysis of our series age is signifi-
cant in OS but not in DSS.
Distant metastasis is also a very strong prognostic fac-
tor in DTC. This has been shown in several others studies 
[16, 18, 21] and is yet reconfirmed. Because of standardi-
zation of radioiodine therapy prognosis may have slightly 
Fig. 1  Kaplan–Meier curve for overall survival in 225 patients displayed with 95% confidence interval
Fig. 2  Kaplan–Meier curve for disease specific survival in 225 patients displayed with 95% confidence interval
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improved for patients with distant metastasis, especially in 
younger patients with lung metastases and 131I-uptake [22].
Godballe et  al. [12] identified both tumor size and 
extrathyroidal invasion as significant prognostic factors in 
univariate analysis, but the significance of size disappeared 
in the multivariate analysis. In the present long-term study 
tumor size remained significant in multivariate analysis of 
NAFCTC, suggesting that both tumor size and extrathyroi-
dal invasion contain prognostic information.
In univariate analysis histological type (papillary ver-
sus follicular) was significant in OS and DSS. Patients 
with follicular carcinoma had a considerable less favorable 
Fig. 3  Kaplan–Meier curve for overall survival in differentiated thyroid carcinoma and Hiltzik criteria group
Fig. 4  Kaplan–Meier curve for disease specific survival in differentiated thyroid carcinoma and Hiltzik criteria group
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prognosis than patients with papillary carcinoma. However, 
this significance was not found in multivariate analysis. 
The result is confirmed in some studies [5, 16, 17], while 
other studies find a prognostic difference [19–21].
Tumor necrosis and tumor mitosis were significant 
independent prognostic factors in OS and DSS in multi-
variate analysis. As mentioned above these factors are used 
in histology grading for PDTC, which is a relatively new 
diagnostic entity [9]. According to the TURIN proposal 
information regarding convoluted nuclei and growth pat-
tern (trabecular/insular/solid) is also required to classify 
PDTC. In our study information about growth pattern was 
not evaluated. Thus application of the TURIN proposal was 
not possible. However, the Hiltzik criteria only required the 
high-grade features tumor necrosis and/or mitosis. When 
the NAFCTC patients were divided according to the Hiltzik 
criteria (Fig. 2), 153 patients were classified as DTC and 66 
patients as PDTC. Compared to several other studies this 
model displayed similar 10-year survival exceeding 90% 
[5, 19, 23] for DTC. In PDTC 5-year OS has been reported 
from 60 to 73% [7, 11, 24], which is comparable to the 
5-year OS at 57% in this study. Our findings support that 
tumor necrosis and/or mitosis according to Hiltzik criteria 
identify a group of patients with an intermediate prognosis 
equivalent to PDTC.
Due to the long follow-up time this study showed some 
interesting recurrences. Four patients in our study had their 
first recurrence more than 10 years after initial treatment. 
In one case the patient had the first recurrence 27 years 
after initial treatment and died 5 years later from thyroid 
carcinoma with distant metastases in multiple organs. This 
has also been observed in other long-term follow-up stud-
ies [25]. The findings emphasize the importance of a long 
follow-up time.
Conclusion
Tumor necrosis and mitosis are highly significant prognos-
tic indicators in analysis of long time survival of nonana-
plastic follicular cell-derived thyroid carcinoma indicating 
that a simplification of the actually used criteria for poorly 
differentiated carcinomas may be justified.
Compliance with ethical standards 
Funding No financial support or funding.
Conflict of interest No conflict of interest.
Ethics This article does not contain any studies with animals per-
formed by any of the authors. This study has been approved by the 
Danish Data Protection Agency and The Regional Scientific Ethical 
Committees for Southern Denmark.
Informed consent For this type of study formal consent is not 
required.
Disclosure statement No competing financial interests exist. No 
writing assistance used.
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://
creativecommons.org/licenses/by/4.0/), which permits unrestricted 
use, distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
 1. Blomberg M, Feldt-Rasmussen U, Andersen KK, Kjaer SK 
(2012) Thyroid cancer in Denmark 1943–2008, before and 
after iodine supplementation. Int J Cancer 131(10):2360–2366. 
doi:10.1002/ijc.27497
 2. Sherman SI (2003) Thyroid carcinoma. The Lancet 
361(9356):501–511
 3. Londero SC, Krogdahl A, Bastholt L, Overgaard J, Pedersen 
HB, Frisch T, Bentzen J, Pedersen PU, Christiansen P, Godballe 
C (2013) Papillary thyroid carcinoma in Denmark 1996–2008: 
an investigation of changes in incidence. Cancer Epidemiol 
37(1):e1–e6. doi:10.1016/j.canep.2012.10.011
 4. Londero SC, Krogdahl A, Bastholt L, Overgaard J, Trolle W, 
Pedersen HB, Bentzen J, Schytte S, Christiansen P, Godballe 
C, Danish Thyroid Cancer G (2013) Papillary thyroid micro-
carcinoma in Denmark 1996–2008: a national study of epide-
miology and clinical significance. Thyroid 23(9):1159–1164. 
doi:10.1089/thy.2012.0595
 5. Mazzaferri EL, Jhiang SM (1994) Long-term impact of initial 
surgical and medical therapy on papillary and follicular thyroid 
cancer. Am J Med 97(5):418–428
 6. DeLellis RA et al (2004) Pathology and genetics of tumours of 
endocrine organs. International Agency for Research in Cancer, 
Lyon
 7. Hiltzik D, Carlson DL, Tuttle RM, Chuai S, Ishill N, Shaha A, 
Shah JP, Singh B, Ghossein RA (2006) Poorly differentiated 
thyroid carcinomas defined on the basis of mitosis and necrosis: 
a clinicopathologic study of 58 patients. Cancer 106(6):1286–
1295. doi:10.1002/cncr.21739
 8. Volante M, Collini P, Nikiforov YE, Sakamoto A, Kakudo K, 
Katoh R, Lloyd RV, LiVolsi VA, Papotti M, Sobrinho-Simoes M, 
Bussolati G, Rosai J (2007) Poorly differentiated thyroid carci-
noma: the Turin proposal for the use of uniform diagnostic cri-
teria and an algorithmic diagnostic approach. Am J Surg Pathol 
31(8):1256–1264. doi:10.1097/PAS.0b013e3180309e6a
 9. Volante M, Papotti M (2010) Poorly differentiated thyroid 
carcinoma: 5 years after the 2004 WHO classification of 
endocrine tumours. Endocr Pathol 21(1):1–6. doi:10.1007/
s12022-009-9100-4
 10. Tallini G (2011) Poorly differentiated thyroid carcinoma. Are 
we there yet? Endocr Pathol 22(4):190–194. doi:10.1007/
s12022-011-9176-5
 11. Gnemmi V, Renaud F, Do Cao C, Salleron J, Lion G, Wemeau 
JL, Copin MC, Carnaille B, Leteurtre E, Pattou F, Aubert S 
(2014) Poorly differentiated thyroid carcinomas: application of 
the Turin proposal provides prognostic results similar to those 
 Eur Arch Otorhinolaryngol
1 3
from the assessment of high-grade features. Histopathology 
64(2):263–273. doi:10.1111/his.12246
 12. Godballe C, Asschenfeldt P, Jorgensen KE, Bastholt L, Clausen 
PP, Hansen TP, Hansen O, Bentzen SM (1998) Prognostic fac-
tors in papillary and follicular thyroid carcinomas: p53 expres-
sion is a significant indicator of prognosis. Laryngoscope 
108(2):243–249
 13. Hermanek P, Sobin LH (1987) TNM classification of malignant 
tumours, vol 4., fully rev. ed. Springer, Berlin
 14. Sobin LH, Gospodarowicz MK, Wittekind C (2010) TNM clas-
sification of malignant tumours, vol  7. ed. Wiley-Blackwell, 
Chichester
 15. Bellantone R, Lombardi CP, Boscherini M, Ferrante A, Raffaelli 
M, Rubino F, Bossola M, Crucitti F (1998) Prognostic factors in 
differentiated thyroid carcinoma: a multivariate analysis of 234 
consecutive patients. J Surg Oncol 68(4):237–241
 16. Eustatia-Rutten CF, Corssmit EP, Biermasz NR, Pereira AM, 
Romijn JA, Smit JW (2006) Survival and death causes in differ-
entiated thyroid carcinoma. J Clin Endocrinol Metab 91(1):313–
319. doi:10.1210/jc.2005-1322
 17. Konturek A, Barczynski M, Nowak W, Richter P (2012) Prog-
nostic factors in differentiated thyroid cancer—a 20-year surgi-
cal outcome study. Langenbeck’s. Arch Surg 397(5):809–815. 
doi:10.1007/s00423-011-0899-z
 18. Pelizzo MR, Boschin IM, Toniato A, Piotto A, Pagetta C, 
Gross MD, Al-Nahhas A, Rubello D (2007) Papillary thy-
roid carcinoma: 35-year outcome and prognostic factors in 
1858 patients. Clin Nucl Med 32(6):440–444. doi:10.1097/
RLU.0b013e31805375ca
 19. Sciuto R, Romano L, Rea S, Marandino F, Sperduti I, Maini CL 
(2009) Natural history and clinical outcome of differentiated 
thyroid carcinoma: a retrospective analysis of 1503 patients 
treated at a single institution. Ann Oncol 20(10):1728–1735. 
doi:10.1093/annonc/mdp050
 20. Vorburger SA, Ubersax L, Schmid SW, Balli M, Candinas D, 
Seiler CA (2009) Long-term follow-up after complete resection 
of well-differentiated cancer confined to the thyroid gland. Ann 
Surg Oncol 16(10):2862–2874. doi:10.1245/s10434-009-0592-4
 21. Lundgren CI, Hall P, Dickman PW, Zedenius J (2006) Clini-
cally significant prognostic factors for differentiated thyroid car-
cinoma: a population-based, nested case-control study. Cancer 
106(3):524–531. doi:10.1002/cncr.21653
 22. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli 
JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlum-
berger M (2006) Long-term outcome of 444 patients with distant 
metastases from papillary and follicular thyroid carcinoma: ben-
efits and limits of radioiodine therapy. J Clin Endocrinol Metab 
91(8):2892–2899. doi:10.1210/jc.2005-2838
 23. Gilliland FD, Hunt WC, Morris DM, Key CR (1997) Prognos-
tic factors for thyroid carcinoma. A population-based study of 
15,698 cases from the surveillance, epidemiology and end results 
(SEER) program 1973–1991. Cancer 79(3):564–573
 24. Ibrahimpasic T, Ghossein R, Carlson DL, Nixon I, Palmer 
FL, Shaha AR, Patel SG, Tuttle RM, Shah JP, Ganly I (2014) 
Outcomes in patients with poorly differentiated thyroid carci-
noma. J Clin Endocrinol Metab 99(4):1245–1252. doi:10.1210/
jc.2013-3842
 25. Grogan RH, Kaplan SP, Cao H, Weiss RE, Degroot LJ, Simon 
CA, Embia OM, Angelos P, Kaplan EL, Schechter RB (2013) 
A study of recurrence and death from papillary thyroid cancer 
with 27 years of median follow-up. Surgery 154 (6):1436–1446. 
doi:10.1016/j.surg.2013.07.008. discussion 1446–1437
